Aprea Therapeutics, Inc. — Director's Dealing 2021

Aug 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aprea Therapeutics, Inc. (APRE)
CIK: 0001781983
Period of Report: 2021-08-25

Reporting Person: Coiante Scott M (SVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-25	Common Stock	F	7534	$3.98	Disposed	91466	Direct

Footnotes

F1: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 21,166 restricted stock units.